Green Cross Medical Science Corporation (KOSDAQ:142280)
South Korea
· Delayed Price · Currency is KRW 3,520.00
-115.00 (-3.16%)
At close: Mar 9, 2026
KOSDAQ:142280 Revenue
Green Cross Medical Science had revenue of 26.45B KRW in the quarter ending September 30, 2025, a decrease of -1.77%. This brings the company's revenue in the last twelve months to 111.12B, up 11.43% year-over-year. In the year 2024, Green Cross Medical Science had annual revenue of 103.85B with 10.47% growth.
Revenue (ttm)
111.12B
Revenue Growth
+11.43%
P/S Ratio
0.69
Revenue / Employee
910.80M
Employees
122
Market Cap
76.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.85B | 9.84B | 10.47% |
| Dec 31, 2023 | 94.01B | -19.10B | -16.88% |
| Dec 31, 2022 | 113.11B | 11.43B | 11.25% |
| Dec 31, 2021 | 101.67B | -11.70B | -10.32% |
| Dec 31, 2020 | 113.38B | 31.88B | 39.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB Panagene | 14.29B |
| Protia | 13.52B |
| Cytogen | 25.09B |
| Seoulin Bioscience | 76.74B |
| GeneMatrix | 4.72B |
| GENINUS | 8.81B |
| Median Diagnostics | 7.86B |
| PeopleBio | 3.36B |